Patents by Inventor Timothy John Mitchell
Timothy John Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9370557Abstract: The invention relates to the use of bacterial cytolysin proteins, such as pneumolysin, as adjuvants for stimulating or enhancing immune responses against co-administered target antigens. Desirably, the target antigen is provided as a fusion protein with the cytolysin. The inventors have found that cytolysins may be particularly effective for stimulation of mucosal immune responses against the target antigen.Type: GrantFiled: June 15, 2007Date of Patent: June 21, 2016Assignee: The University Court of the University of GlasgowInventors: Timothy John Mitchell, Lea-Ann Kirkham, Graeme James Cowan, Gillian Douce
-
Patent number: 8877750Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: November 23, 2010Date of Patent: November 4, 2014Assignee: Norgine B.V.Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20110065697Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: ApplicationFiled: November 23, 2010Publication date: March 17, 2011Applicant: Norgine B.V.Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Patent number: 7858617Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: March 7, 2008Date of Patent: December 28, 2010Assignee: Norgine B.V.Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Patent number: 7825113Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: November 27, 2002Date of Patent: November 2, 2010Assignee: Norgine B.V.Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Patent number: 7820789Abstract: The invention relates to immunogenic compositions comprising mutant Streptococcus pneumoniae pneumolysin proteins. The invention further relates to such proteins and nucleic acids encoding these proteins. In particular embodiments, the invention is directed to an isolated mutant pneumolysin (PLY) protein, wherein the mutant PLY protein differs from the wild-type PLY protein of SEQ ID NO:1 presence of a mutation within the region of amino acids 144 to 161 of the wild type such that the toxicity of the mutant is reduced relative to that of the wild-type protein. In particular embodiments, the mutant PLY protein differs from the wild-type protein by the substitution or deletion of amino acids including the deletion of two adjacent amino acids within the region of amino acids 144 to 151 of the wild-type sequence.Type: GrantFiled: May 9, 2005Date of Patent: October 26, 2010Inventors: Lea-Ann Stirling Kirkham, Timothy John Mitchell
-
Patent number: 7776853Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: November 27, 2002Date of Patent: August 17, 2010Assignee: Norgine B.V.Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20100166795Abstract: The invention relates to the use of bacterial cytolysin proteins, such as pneumolysin, as adjuvants for stimulating or enhancing immune responses against co-administered target antigens. Desirably, the target antigen is provided as a fusion protein with the cytolysin. The inventors have found that cytolysins may be particularly effective for stimulation of mucosal immune responses against the target antigen.Type: ApplicationFiled: June 15, 2007Publication date: July 1, 2010Inventors: Timothy John Mitchell, Lea-Ann Kirkham, Graeme James Cowan, Gillian Douce
-
Publication number: 20080161301Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: ApplicationFiled: March 7, 2008Publication date: July 3, 2008Applicant: Alizyme Therapeutics LimitedInventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20080112964Abstract: The invention relates to immunogenic compositions comprising mutant Streptococcus pneumoniae pneumolysin proteins. The invention further relates to such proteins and nucleic acids encoding these proteins. In particular embodiments, the invention is directed to an isolated mutant pneumolysin (PLY) protein, wherein the mutant PLY protein differs from the wild type PLY protein by the presence of a mutation within the region of amino acids 144 to 161 of the wild type sequence, such that the toxicity of the mutant is reduced relative to that of the wild-type protein. In particular embodiments, the mutant PLY protein differs from the wild type protein by the substitution or deletion of amino acids within this region, including the deletion of two adjacent amino acids within the region of amino acids 144 to 151 of the wild type sequence.Type: ApplicationFiled: May 9, 2005Publication date: May 15, 2008Inventors: Lea-Ann Stirling Kirkham, Timothy John Mitchell
-
Patent number: 6716432Abstract: Mutants of pneumolysin that are non-toxic by reason of amino acid substitutions have been constructed. These mutants elicit an immune response in animals that is reactive to wild-type pneumolysin. The invention also encompasses vaccines for humans based on these mutants, including vaccines comprising conjugates with pneumococcal capsular polysaccharides.Type: GrantFiled: January 25, 1995Date of Patent: April 6, 2004Inventors: James Cleland Paton, David John Hansman, Graham John Boulnois, Peter William Andrew, Timothy John Mitchell, John Arthur Walker
-
Patent number: 6656934Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: July 6, 2001Date of Patent: December 2, 2003Assignee: Alizyme Therapeutics LimitedInventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20030195206Abstract: The use of a compound comprising formula (I): 1Type: ApplicationFiled: November 27, 2002Publication date: October 16, 2003Inventors: Harold Francis Hodson, Robert Downham, Timothy john Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20030191123Abstract: The use of a compound comprising formula (I): 1Type: ApplicationFiled: November 27, 2002Publication date: October 9, 2003Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Patent number: 6624161Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.Type: GrantFiled: July 6, 2001Date of Patent: September 23, 2003Assignee: Alizyme Therapeutics LimitedInventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20030027821Abstract: The use of a compound comprising formula (I): 1Type: ApplicationFiled: July 6, 2001Publication date: February 6, 2003Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Publication number: 20030013707Abstract: The use of a compound comprising formula (I): 1Type: ApplicationFiled: July 6, 2001Publication date: January 16, 2003Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
-
Patent number: 6436065Abstract: In accordance with the present invention there is provided an upper body support characterized by a dorsal member, having a lower portion which extends substantially rearwardly of a wearer, and at least one flexibly resilient element operatively interconnected with the lower portion of the dorsal member so that when the wearer bends at the waist, the dorsal member operates on the or each flexible resilient element in such a manner that the weight of the upper body of the wearer is borne at least partly therethrough.Type: GrantFiled: November 1, 2000Date of Patent: August 20, 2002Assignee: Bendezy PTY LTDInventor: Timothy John Mitchell